Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (otvara novi prozor)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Izvor‎: Cancer 2013;119(21):3784-7.

Indeks‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (otvara novi prozor)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (otvara novi prozor)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Izvor‎: Lancet 1989;334(8655):122-4.

Indeks‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (otvara novi prozor)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (otvara novi prozor)

Ben-Bassat I, Douer D, Ramot B.

Izvor‎: Eur J Haematol 1990;45(2):86-9.

Indeks‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (otvara novi prozor)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (otvara novi prozor)

Dean A, Tuffin P.

Izvor‎: J Pain Symptom Manage 1997;13(1):20-4.

Indeks‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (otvara novi prozor)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (otvara novi prozor)

Ford PA, Grant SJ, Mick R, Keck G.

Izvor‎: J Clin Oncol 2015;33(15):1674-9.

Indeks‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (otvara novi prozor)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (otvara novi prozor)

Garewal HS, Durie BG.

Izvor‎: Scand J Haematol 1985;35(5):497-500.

Indeks‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (otvara novi prozor)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (otvara novi prozor)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Izvor‎: Cancer 2006;107(1):136-40.

Indeks‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (otvara novi prozor)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (otvara novi prozor)

Marshall A, Li A, Drucker A, Dzik W.

Izvor‎: Hematol Oncol 2016;34(3):147-53.

Indeks‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (otvara novi prozor)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (otvara novi prozor)

Prokopchuk-Gauk O, Brose K.

Izvor‎: Cureus 2015;7(12):e428.

Indeks‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (otvara novi prozor)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (otvara novi prozor)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Izvor‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indeks‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (otvara novi prozor)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (otvara novi prozor)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Izvor‎: Hematol Oncol 2008;26(4):241-6.

Indeks‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (otvara novi prozor)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (otvara novi prozor)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Izvor‎: Am J Hematol 2006;81(9):720.

Indeks‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (otvara novi prozor)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (otvara novi prozor)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Izvor‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indeks‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (otvara novi prozor)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (otvara novi prozor)

Erduran E, Bahadir A, Mutlu M.

Izvor‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indeks‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (otvara novi prozor)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (otvara novi prozor)

Franchini M, Veneri D, Lippi G.

Izvor‎: Bone Marrow Transplant 2007;39(12):729-35.

Indeks‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (otvara novi prozor)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (otvara novi prozor)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Izvor‎: Am J Hematol 2002;69(3):219-22.

Indeks‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (otvara novi prozor)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (otvara novi prozor)

Hsieh A, Cheong I.

Izvor‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indeks‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (otvara novi prozor)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (otvara novi prozor)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Izvor‎: Haemostasis 1996;26 Suppl 1:159-64.

Indeks‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (otvara novi prozor)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (otvara novi prozor)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Izvor‎: Med Oncol 2010;27(1):16-9.

Indeks‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (otvara novi prozor)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (otvara novi prozor)

Vidarsson B, Önundarson PT.

Izvor‎: Thromb Haemost 2000;83(4):634-5.

Indeks‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (otvara novi prozor)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (otvara novi prozor)

Zver S, Andoljšek D, Černelč P.

Izvor‎: Eur J Haematol 2004;72(6):455-6.

Indeks‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (otvara novi prozor)

Management of bleeding complications of hematologic malignancies. (otvara novi prozor)

Green D.

Izvor‎: Semin Thromb Hemost 2007;33(4):427-34.

Indeks‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (otvara novi prozor)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (otvara novi prozor)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Izvor‎: Int J Lab Hematol 2013;35(4):457-9.

Indeks‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (otvara novi prozor)

Management of bleeding in patients with advanced cancer. (otvara novi prozor)

Pereira J, Phan T.

Izvor‎: Oncologist 2004;9(5):561-70.

Indeks‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (otvara novi prozor)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (otvara novi prozor)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Izvor‎: Haematologica 1997;82(5):584-7.

Indeks‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (otvara novi prozor)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (otvara novi prozor)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Izvor‎: Bull Cancer 2006;93(2):E7-12.

Indeks‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (otvara novi prozor)